Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of BRAF Inhibitor Resistance-associated lncRNAs Using Genome-scale CRISPR-Cas9 Transcriptional Activation Screening.

Anticancer research - 1 Jun 2024

Wen Xuan, Han Min, Hosoya Masaki, Toshima Rika, Onishi Mai, Fujii Tomoaki, Yamaguchi Shigeo, Kato Shunsuke

Abstract excerpt

BACKGROUND/AIM: Approximately 50% of melanomas harbor the BRAF V600E mutation and targeted therapies using BRAF inhibitors improve patient outcomes. Nonetheless, resistance to BRAF inhibitors develops rapidly and remains a challenge in melanoma treatment. In this study, we attempted to isolate long noncoding RNAs (lncRNAs) involved in BRAF inhibitor resistance using a comprehensive screening method. MATERIALS AND...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR-Cas Systems
Share to Gene Regulatory Networks

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to Melanoma

Share to Oximes

Share to Proto-Oncogene Proteins B-raf

Share to RNA, Long Noncoding

Share to Transcriptional Activation

Source

Identifiers

PMID: 38821628
DOI: 10.21873/anticanres.17042

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of BRAF Inhibitor Resistance-associated lncRNAs Using Genome-scale CRISPR-Cas9 Transcriptional Activation Screening.PMID 38821628Read ↗

CRISPR Screens Identify Essential Cell Growth Mediators in BRAF Inhibitor-resistant Melanoma.Semantic proximity Read ↗

CRISPR Screens Identify Essential Cell Growth Mediators in BRAF-inhibitor Resistant MelanomaSemantic proximity Read ↗

CRISPR-inhibition screen for lncRNAs linked to melanoma growth and metastasisSemantic proximity Read ↗

Genome-scale activation screen identifies a lncRNA locus regulating a gene neighbourhood.Semantic proximity Read ↗

Non-coding RNAs in BRAF-mutant melanoma: targets, indicators, and therapeutic potential.Semantic proximity Read ↗

Identification of pathways modulating Vemurafenib resistance in melanoma cells via a genome-wide CRISPR/Cas9 screenSemantic proximity Read ↗

Genome-wide CRISPR Screening Identifies NFκB and c-MET as Druggable Targets to Sensitize Lenvatinib Treatment in Hepatocellular CarcinomaSemantic proximity Read ↗

Identification of pathways modulating vemurafenib resistance in melanoma cells via a genome-wide CRISPR/Cas9 screen.Semantic proximity Read ↗

miR-524-5p reduces the progression of the BRAF inhibitor-resistant melanoma.Semantic proximity Read ↗

Clinically relevant genes and regulatory pathways associated with NRASQ61 mutations in melanoma through an integrative genomics approach.Semantic proximity Read ↗

Landscape of enhancer disruption and functional screen in melanoma cells.Semantic proximity Read ↗

Differential Gene Expression Common to Acquired and Intrinsic Resistance to BRAF Inhibitor Revealed by RNA-Seq AnalysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.